Ocugen, Inc. (OCGN)
| Market Cap | 493.84M |
| Revenue (ttm) | 7.05M |
| Net Income (ttm) | -58.50M |
| Shares Out | 257.33M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,343,630 |
| Open | 1.930 |
| Previous Close | 1.910 |
| Day's Range | 1.870 - 1.970 |
| 52-Week Range | 0.345 - 2.105 |
| Beta | 3.80 |
| Analysts | Strong Buy |
| Price Target | 4.67 (+143.23%) |
| Earnings Date | May 14, 2024 |
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy un... [Read more]
Financial Performance
In 2023, Ocugen's revenue was $6.04 million, an increase of 142.60% compared to the previous year's $2.49 million. Losses were -$63.08 million, -27.33% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price forecast is $4.67, which is an increase of 143.23% from the latest price.
News
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell ...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com...
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com...
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
NEW YORK , May 17, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, b...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com...
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com...
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com...
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and c...
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES , May 15, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Comp...
Ocugen Provides Business Update with First Quarter 2024 Financial Results
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progress OCU400 on track to meet 2026 Biologics License Application (BLA) and Market Au...
ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
New York , May 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, b...
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell ...
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com...
Ocugen to Present at May 2024 Investor Conferences
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and c...
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Comp...
Ocugen stock is a good speculative buy but there's 1 key risk
Ocugen (NASDAQ: OCGN) stock price has launched higher since last year, helped by the rising hopes that OCU400 will be approved by the Food and Drug Administration (FDA). The stock surged by over 378% ...
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Comp...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
NEW YORK , May 3, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) a...
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell ...
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell ...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Ocugen, Inc. (“Oc...
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advised...
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...